Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | PTK2 |
| Gene Name: | PTK2 |
| Protein Full Name: | Focal adhesion kinase 1 |
| Alias: | EC 2.7.10.2; FADK1; FAK1; Pp125FAK; Protein-tyrosine kinase 2; PTK2 |
| Mass (Da): | 119233 |
| Number AA: | 1052 |
| UniProt ID: | Q05397 |
| Locus ID: | 5747 |
| COSMIC ID: | PTK2 |
| Gene location on chromosome: | 8q24.3 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 8446 |
| Percent of cancer specimens with mutations: | 0.84 |
| Found in amplified chromosomal regions in human cancers: | amplified in small cell lung cancer and GI tract cancers |
| Normal role description: | PTK2 is a non-receptor protein-tyrosine kinase that is activated by tyrosine-phosphorylation in response to integrin clustering induced by cell adhesion or antibody cross-linking, or via G-protein coupled receptor (GPCR) occupancy by ligands. Serves as adaptor protein. Linked to the MAPK pathway via Grb2. Linked to PI3K and PLC gamma pathways. Role as scaffold for MDM2-mediated p53 degradation. Implicated in regulation of cell-cell contacts, microtubule stability and control of gene transcription. High expression levels in various human cancers. Promotes tumour cell motility, matrix degradation, angiogenesis and suppresses apoptosis, anoikis and senescence. |